Fig. 2From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancerMean standardized uptake value (SUVmean) with a standard error of 64Cu-NOTA-Trastuzumab in normal organs and maximum standardized uptake value (SUVmax) with a standard error of 64Cu-NOTA-Trastuzumab in tumorsBack to article page